Varuma AG
Overview
Varuma AG is a Swiss venture capital firm headquartered in Basel, specializing in investments within the healthcare sector. The firm focuses on late-stage ventures, providing capital to companies in the pharmaceutical and biotechnology industries. Varuma's investment strategy emphasizes supporting businesses that are poised for significant growth and market impact. The firm's portfolio includes notable companies such as NovImmune, Addex Therapeutics, and Santhera Pharmaceuticals. These investments reflect Varuma's commitment to advancing innovative healthcare solutions and fostering the development of cutting-edge medical technologies. By partnering with these companies, Varuma aims to contribute to the evolution of the healthcare landscape. Varuma AG operates with a team of experienced professionals, including Management Partner Hans-Beat Gürtler, who has a background as the Global Chief Executive Officer at Novartis Animal Health. The firm's leadership brings a wealth of expertise in managing and scaling healthcare enterprises, ensuring strategic guidance and value creation for its portfolio companies.
Investment Focus
- Late Stage Venture
- Healthcare Sector
- Switzerland
Portfolio Companies
Reach Varuma AG directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Varuma AG
What sectors does Varuma AG invest in?
Varuma AG invests in Pharmaceuticals and Biotechnology, and is based in Basel-Stadt, Switzerland. Varuma AG is listed as a venture capital in the ConnectSafely investor database.
Which regions does Varuma AG invest in?
Varuma AG invests across Switzerland.
What companies has Varuma AG invested in?
Varuma AG's portfolio includes Santhera Pharmaceuticals, Novimmune and Addex Therapeutics.
Last updated · Source: ConnectSafely investor database
